Reimbursement

There are still significant unresolved issues in artificial intelligence and machine learning, which must be addressed before they can be safely and effectively used more broadly in medicine.

Asking pharmacists to do even more work while paring down their support is not a sustainable solution to increasing costs.

The law directs federal spending toward funding the internal revenue service, improving taxpayer compliance, lowering health care needs, and reducing carbon emissions.

Screening tools are becoming widely used to help clinicians address the needs of patients with diabetes to improve health outcomes.

Given the increasing value of patient satisfaction in determining the quality of care in the hospital reimbursement model, research is flourishing with a focus on identifying the factors that could positively influence patient satisfaction outcomes.

Nearly 84% of hospitals are working to prevent and mitigate burnout, with increased support and programs for individual wellness and resilience practices.

The crucial role of self-care pharmacy practice requires that pharmacists develop a robust understanding of the implications of the current and proposed regulatory changes for nonprescription drugs.

Choosing the best biosimilar based on reimbursement can be challenging.

Although payers have become somewhat accustomed to the high cost of specialty drugs, the price tags for gene therapies are causing “sticker shock.”

Pharmacy professionals can bring in the right people at the right time to identify needed changes and develop an action plan.

It is a means of supporting the growing provider status movement, which could enable clinical practice growth.

Studies show that patients who are introduced to patient support programs through digital platforms are more likely to use support services.

Remote work has been a growing trend across many different areas of pharmacy.

Although community oncology has grown, maintaining services for patients is an ongoing challenge.

Although state efforts can be impactful, Downs said enforcement is a major hurdle.

Despite tensions that can occur, building relationships with health systems and finding opportunities to collaborate is crucial to improve cancer care.

Shiela Plasencia, director of practice support at the Community Oncology Alliance, discussed COA’s new tool to help practices prepare for the Enhancing Oncology Model.

Nick Ferreyros, managing director of policy, advocacy, and communications at the Community Oncology Alliance, discussed the Alliance’s efforts surrounding PBMs and 340B reform.

Most patients used nonproprietary drugs, which may contribute to the reduction of out-of-pocket costs for the treatment of invasive breast cancer.

The changes, which will be effective January 1, 2024, include pre-filled pens, vials of basal, vials of bolus, and pre-mix insulins.

Pharmacists should continue to seek out opportunities to be involved in family medicine and chronic disease state management to make meaningful impacts on care.

Pharmacy departments can be one of the most expensive departments in a cancer center practice, but the revenue generated for its services typically far outpaces associated costs.

Study participants without co-pays were slightly more likely to take their medications as prescribed for several medication classes.

They can continue to put pressure on companies and regulatory bodies to make the system work for them and not the other way around.

Pharmacists play a vital role in ensuring that patients can afford their medications, either by advising them on more affordable options or working with insurers and prescribers to find cheaper alternatives.

The company is also launching Rezvoglar, a biosimilar to Lantus injection, for $92 per 5-pack of KwikPens.

AI models can predict pharmacy foot traffic and peak service times, and even analyze patient histories to single out who picks up their prescriptions on time.

Understanding the complicated web of insurers, discounts from government and commercial plans, and payer access is extremely complicated.

The ability—or lack thereof—to procure drugs can drive prices up and decrease patient accessibility.

Analysis shows average monthly premiums for stand-alone plans will rise 10% to $43.